-- 据周三提交给印度证券交易所的文件显示，Zydus Lifesciences（NSE：ZYDUSLIFE，BOM：532321）位于印度艾哈迈达巴德Zydus生物科技园的9号工厂在接受美国食品药品监督管理局（FDA）检查后，收到了七项观察意见。 监管机构于4月27日至5月5日对艾哈迈达巴德工厂进行了检查。 该公司计划与FDA密切合作，尽快解决这些问题。 该公司股价在近期交易中上涨了近3%。
Related Articles
Mining & Metals
Earnings Flash (SDE.TO) Spartan Delta Corp. Increased 2026 Guidance and Increase To Credit Facility
$SDE.TO
Asia
ValueMax Raises SG$24 Million Through Digital Securities Issuance
ValueMax (SGX:T6I) raised over SG$23.9 million through the issuance of digital securities on the SDXX platform, according to a Wednesday filing with the Singapore Exchange.The issuance will be listed on the SDXX platform on May 7, the filing added.
$SGX:T6I
Mining & Metals
Earnings Flash (ADEN.TO) ADENTRA Posted Q1 Adjusted EPS US$0.38 per Share, vs. FactSet Est of $0.31
$ADEN.TO